Article
Biochemistry & Molecular Biology
Ting-An Yie, Cynthia A. Loomis, Johannes Nowatzky, Alireza Khodadadi-Jamayran, Ziyan Lin, Michael Cammer, Clea Barnett, Valeria Mezzano, Mark Alu, Jackson A. Novick, John S. Munger, Matthias C. Kugler
Summary: Normal lung development relies on the coordinated action of HH and PDGF signaling pathways, which are crucial for mesenchymal differentiation and proliferation. Recent studies have shown that HH is necessary for alveolar myofibroblast differentiation. In this study, we investigated the relationship between HH and PDGF signaling during postnatal lung development in mice. Our findings suggest that HH and PDGF signaling pathways intersect to support myofibroblast function during secondary alveolar septum formation.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Haijun Wang, Jie Yang, Ke Zhang, Jia Liu, Yushan Li, Wei Su, Na Song
Summary: Hepatocellular carcinoma (HCC) is a primary liver cancer with increasing incidence and mortality rates globally. The FGF/FGFR signaling axis has been shown to play an important role in HCC development, and targeted therapies are currently being developed to inhibit this pathway.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Xiuqin Jia, Ming Xin, Juanjuan Xu, Xindong Xiang, Xuan Li, Yuhan Jiao, Lulin Wang, Jingjing Jiang, Feng Pang, Xianzhen Zhang, Jian Zhang
Summary: In this study, the FGFRs inhibitor FIIN-2 was found to inhibit the proliferation, colony formation, and migration of platinum-resistant LUAD cells while inducing mitochondria-mediated apoptosis. Furthermore, FIIN-2 was shown to enhance autophagy flux in these cells, suggesting its potential as a treatment strategy for LUAD, especially in combination with autophagy inhibitors.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Aurelien Justet, Mada Ghanem, Tiara Boghanim, Mouna Hachem, Eirini Vasarmidi, Madeleine Jaillet, Aurelie Vadel, Audrey Joannes, Pierre Mordant, Philippe Bonniaud, Martin Kolb, Lei Ling, Aurelie Cazes, Herve Mal, Arnaud Mailleux, Bruno Crestani
Summary: This study identifies FGF19 as an antifibrotic molecule with potential therapeutic interest in fibrotic lung disorders. In vivo and in vitro experiments demonstrate that FGF19 can decrease lung fibrosis and fibrotic markers, modulate apoptosis of lung epithelial cells, and prevent myofibroblast differentiation.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Ana L. Graca, Manuel Gomez-Florit, Hugo Osorio, Marcia T. Rodrigues, Rui M. A. Domingues, Rui L. Reis, Manuela E. Gomes
Summary: This study produced and characterized platelet-derived EVs and investigated their effects on different cell types. The EVs were found to regulate stem cell differentiation, promote angiogenesis, and modulate macrophage polarization, suggesting their potential as therapeutic tools in tissue engineering and regenerative medicine.
Review
Oncology
Patrick L. Mulcrone, Roland W. Herzog, Weidong Xiao
Summary: Gene therapy is a powerful biological tool that is reshaping the therapeutic landscape for various diseases, particularly in the field of cancer, showing promising potential for groundbreaking advances.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Biochemistry & Molecular Biology
Susan Y. S. Li, Rebecca Johnson, Leon C. D. Smyth, Mike Dragunow
Summary: This review provides an updated overview of the actions of platelet-derived growth factors on neurovascular function, their role in regulating perivascular cell types, and their clinical relevance and therapeutic potential for neurological diseases.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2022)
Article
Multidisciplinary Sciences
Iksen Iksen, Wasita Witayateeraporn, Tanakrit Wirojwongchai, Chutipa Suraphan, Natapol Pornputtapong, Natsaranyatron Singharajkomron, Hien Minh Nguyen, Varisa Pongrakhananon
Summary: Lung cancer is a major global health issue, and its management remains a significant challenge. By using network pharmacology methods, potential targets of Aspiletreins in non-small cell lung cancer (NSCLC) were identified, including STAT3, VEGFA, HSP90AA1, FGF2, and IL2. This study provides a powerful tool for investigating the mechanism of new drug targets on specific diseases.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Xu Zhou, Ruth A. Franklin, Miri Adler, Trevor S. Carter, Emily Condiff, Taylor S. Adams, Scott D. Pope, Naomi H. Philip, Matthew L. Meizlish, Naftali Kaminski, Ruslan Medzhitov
Summary: This article reports on the mechanisms controlling the population numbers of different cell types in animal tissues. The study shows that fibroblasts are limited in proliferation due to space availability, while macrophages are constrained by growth factor availability. The transcriptional coactivator YAP1 in fibroblasts directly regulates the expression of the macrophage-specific growth factor Csf1. The findings suggest that tissue environment sensing is a general strategy for controlling tissue composition.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Engineering, Biomedical
Harsha Kabra, Tanaya Walimbe, Kate Stuart, Camille Indey, Swati Jalgaonkar, Elvis Ikwa, Taylor Skurnac, Julia Chen, Andrew Woolley, Nicholas M. Snead, Nathan Bachtell, Diana J. Leeming, Morten Karsdal, Glenn Prestwich, Alyssa Panitch, John Paderi
Summary: SBR-294, targeting collagen-mediated platelet activation and PDGF activity, showed potential therapeutic benefits in reducing liver fibrosis in the CCl4 mouse model. Further investigation is warranted to explore its potential as a treatment for liver fibrosis.
Article
Pathology
Hely Ollila, Juuso Paajanen, Henrik Wolff, Ilkka Ilonen, Eva Sutinen, Katja Valimaki, Arne ostman, Sisko Anttila, Eeva Kettunen, Jari Rasanen, Olli Kallioniemi, Marjukka Myllarniemi, Mikko Mayranpaa, Teijo Pellinen
Summary: In malignant pleural mesothelioma, specific markers in tumor cells and stromal fibroblasts are associated with patient survival, with PDGFRB and SPARC identified as potential markers for risk stratification and therapy.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2021)
Article
Reproductive Biology
Corrine F. Monaco, Michele R. Plewes, Emilia Przygrodzka, Jitu W. George, Fang Qiu, Peng Xiao, Jennifer R. Wood, Andrea S. Cupp, John S. Davis
Summary: During the regression of the ovarian corpus luteum, fibroblasts are responsible for rapid matrix remodeling. However, little is known about the role of fibroblasts in the functional or regressing corpus luteum. In this study, it was found that FGF2 activates luteal fibroblasts, leading to collagen production and cell proliferation.
BIOLOGY OF REPRODUCTION
(2023)
Review
Oncology
Yiming Zhou, Sizheng Sun, Tao Ling, Yongzhen Chen, Rongzhong Zhou, Qiang You
Summary: FGF18, a member of the FGF family, can promote the occurrence and development of malignant tumors in various systems and has significant clinical implications as a potential therapeutic target and prognostic biomarker.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Xinyi Chen, Hanle Wang, Hui Chen, Ling Ren, Wei Wang, Jingjie Xu, Chenqi Luo, Peike Hu, Qiuli Fao, Ke Yao
Summary: We aimed to create a regenerated lens with biological function to treat cataracts. By inducing human embryonic stem cells to differentiate into lens-like cells, mixing them with hyaluronate, and implanting the mixture into the lens capsule, we successfully achieved near-complete lens regeneration. The regenerated lens exhibited characteristics similar to natural lenses and offers a new therapeutic strategy for cataracts and other lens diseases.
Article
Cell Biology
Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J. Gutierrez, Jacques De Greve
Summary: In this study, a high-throughput siRNA kinome screen was performed to identify targets involved in functional drug tolerance against EGFR TKI in NSCLC. STYK1 was identified as a potential target that, when downregulated, enhances the effects of EGFR inhibition. The study also found that STYK1 selectively interacts with mutant EGFR and that its downregulation counteracts the upregulation of FGF1 induced by EGFR TKI. Co-targeting EGFR and STYK1 could lead to a better overall outcome for NSCLC patients.
CELL DEATH & DISEASE
(2022)
